Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Gelnique Approved for Overactive Bladder


A topical gel for treating symptoms

WEDNESDAY, Jan. 28 (HealthDay News) -- The U.S. Food and Drug Administration has approved Watson Pharmaceuticals' Gelnique (oxybutynin chloride) to treat symptoms of overactive bladder, the company said in a news release.

Gelnique is a topical gel that's applied daily to the thigh, abdomen, upper arm or shoulder. Since it's absorbed through the skin, it's not metabolized by the liver as it would be were the drug's active ingredient, oxybutynin, taken orally, Watson said.

The most frequent side effects reported during clinical testing included dry mouth and reactions where the gel was applied.

Overactive bladder, with symptoms including incontinence, urgency and waking up at night to urinate, affects as many as 33 million adults in the United States, the company said.

More information

The U.S. National Institute on Aging has more on urinary incontinence.

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision